Clinical trials: Skin Toxicity
Breast Cancer, eHealth
Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects
Chemotherapy induces side effects varying in severity, impacting patients' quality of life and necessitating unplanned hospital care. Patient-reported outcomes (PROs) could aid in early detection and management of side effects.
- Conditions
- Breast Cancer, eHealth, Symptom Monitoring, Self Management
- Trial name
- eChemoCoach (NCT06424054)
- Testing
- eChemoCoach
- Volunteers
- 746 people
- Sponsor
- Noordwest Ziekenhuisgroep
EGFRI Induced Acneiform Lesions
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade…
- Trial name
- NCT04759664
- Testing
- LUT014 Gel (Dose 1), LUT014 Gel (Dose 2)
- Where
- 20 sites in United States, Israel
- Volunteers
- 117 people
- Sponsor
- Lutris Pharma Ltd.
Breast Cancer, Breast Cancer Stage II
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
This purpose of this study is to examine skin reactions (called radiation dermatitis) that occur during pencil beam scanning (PBS) proton therapy.
- Conditions
- Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I
- Trial name
- NCT06006806
- Testing
- Pencil Beam Scanning Proton Therapy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Covenant Health Cancer Center
Breast Cancer, Ductal Carcinoma in Situ
Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity
This study will be an open-label prospective observational trial designed to test associations between polymorphisms of candidate genes and tamoxifen.
- Trial name
- NCT00886535
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Milton S. Hershey Medical Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
This study evaluates the immune related toxicity and symptom burden in chronic cancer survivors with melanoma who are receiving adjuvant immunotherapy with immune checkpoint inhibitors.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT04990726
- Testing
- Assessment, Biospecimen Collection, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- M.D. Anderson Cancer Center
Male Breast Cancer, Recurrent Bladder Cancer
Decitabine in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of decitabine in treating patients with advanced solid tumors that have not responded to previous treatment.
- Conditions
- Male Breast Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Melanoma
- Trial name
- NCT00030615
- Testing
- decitabine, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Lung Cancer
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.
Novel treatment modalities like targeted therapies and Immune checkpoint inhibitors have revolutionised the therapeutic landscape in oncology and hematology, significantly improving outcomes even in clinical contexts in which…
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Head and Neck Cancer
- Trial name
- POSITive (NCT06321640)
- Testing
- Cohort A: primarily operable disease, candidate to adjuvant, Cohort B: locally advanced disease, Cohort C: metastatic disease
- Where
- Italy
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Breast Cancer, Chemotherapeutic Toxicity
Neurovascular Changes Induced by Chemotherapy
The purpose of the present study was to test the hypothesis that doxorubicin and cyclophosphamide adjuvant chemotherapy (CHT) acutely induces neurovascular and hemodynamic changes in patients with breast cancer.
- Trial name
- NCT03339804
- Testing
- Chemotherapy
- Where
- Brazil
- Volunteers
- 16 people
- Sponsor
- University of Sao Paulo General Hospital
Renal Cell Carcinoma, Hepatocellular Carcinoma
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
Skin toxicity is a frequently observed side effect in the era of "molecularly targeted therapies". Skin toxicity following administration of protein kinase inhibitors such as sorafenib, regorafenib, lapatinib, sunitinib, and…
- Conditions
- Renal Cell Carcinoma, Hepatocellular Carcinoma, Colorectal Carcinoma
- Trial name
- NCT01466504
- Testing
- skin punch biopsy
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Neoplasms, Colorectal Neoplasms
Limiting Chemotherapy Side Effects by Using Moxa
This study investigates whether it is feasible to teach cancer patients undergoing chemotherapy to self-administer daily moxibustion to reduce chemotherapy side effects.
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Genital Neoplasms, Female, Toxicity Due to Chemotherapy
- Trial name
- NCT02781155
- Testing
- Moxibustion
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- East and North Hertfordshire NHS Trust
Solid Tumor
First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
This is a Phase 1, first-in-human, open-label, non-randomized, dose escalation, trial to explore the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity signals of MSC2363318A.
- Trial name
- NCT01971515
- Testing
- MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen
- Where
- 15 sites in United States
- Volunteers
- 101 people
- Sponsor
- EMD Serono
Colorectal Cancer, Metastases
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
The study is a two-arm randomised phase III trial. Patients will be randomised to receive capecitabine (arm A) or S-1 (arm B). Bevacizumab may be added according to the choice of the investigator.
- Trial name
- SALTO (NCT01918852)
- Testing
- Capecitabine, Teysuno, Bevacizumab
- Where
- 24 sites in Netherlands
- Volunteers
- 161 people
- Sponsor
- Dutch Colorectal Cancer Group
Breast Neoplasms
Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer
This is a multi-center, open-label, phase I/IIa trial, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of estetrol for the treatment of patients with advanced breast cancer.
- Trial name
- NCT02718144
- Testing
- Estetrol
- Where
- 2 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Pantarhei Oncology B.V.
Colorectal Cancer, Non-Small Cell Lung Cancer
Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4
Primary Objective: Correlation of the skin and/or eye toxicity grade secondary to Cetuximab or Panitumumab and the SNP profile of the Epidermal Growth Factor Receptor (EGFR) domain III region.
- Trial name
- NCT01726309
- Where
- 10 sites in Ireland
- Volunteers
- 161 people
- Sponsor
- Cancer Trials Ireland
Neoplasia, Cancer
Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial
Hypothesis: Fasting before (48h) and one day after chemotherapy may protect normal cells from the adverse effects of chemotherapy.
- Conditions
- Neoplasia, Cancer, Fasting
- Trial name
- FIT (NCT01954836)
- Testing
- initial fasting, Secondary fasting
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Charite University, Berlin, Germany
Breast Cancer
Effect of an Amino Acids and Flavonoids Containing FSMP on Chemotherapy Toxicity, Nutritional Status and Quality of Life in Breast Cancer Patients
The goal of this clinical trial is to compare the effect of a Food for Special Medical Purposes (FSMP) mainly containing amino acids and flavonoids in combination with nutritional counseling, versus nutritional counseling alone…
- Trial name
- NCT05968677
- Testing
- FSMP, Nutritional counseling
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Flavolife Srl
Cutaneous Melanoma, Cutaneous Melanoma, Stage III
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer.
- Conditions
- Cutaneous Melanoma, Cutaneous Melanoma, Stage III, Cutaneous Melanoma by AJCC V7 Stage, Cutaneous Melanoma, Stage IV
- Trial name
- NCT07148245
- Testing
- Blood Sample, Health Related Quality of Life Questionnaires (HRQoL), Medical Chart Review
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, San Francisco
Breast Radiotherapy Toxicity
Quantification of Breast RadioTherapy Associated Late Toxicity Using Novel UltraSound Techniques
Around 20% of women who receive breast radiotherapy (RT) experience moderate to severe breast hardening and shrinkage. These side-effects have been shown to be important factors influencing quality of life after breast…
- Trial name
- QuaRTUS (NCT02388230)
- Testing
- Ultrasound imaging
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Head and Neck Cancer, Skin Reactions Secondary to Radiation Therapy
Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but may cause skin irritation and inflammation. Biafine cream may be effective in lessening side effects caused by radiation therapy.
- Trial name
- NCT00006481
- Testing
- Biafine cream, quality-of-life assessment, radiation therapy
- Where
- 260 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.
- Trial name
- Drugs-SNPs (NCT06062810)
- Testing
- Raloxifene - Usual, Raloxifene - Study
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair